IFNG and myeloid sarcoma: Targets and biomarkers utilised to evaluate sex-specific responses to IFN-β therapy in MS encompass pathways that serve as counterparts in male and female regulatory mechanisms governing immunological and neurological homeostasis, such as the IL-6 and IFN-γ pathways.